Breakthrough Response Observed in Amplia's Pancreatic Cancer Trial

June 16, 2025 12:56 PM AEST | By Team Kalkine Media

Breakthrough Response Observed in Amplia's Pancreatic Cancer Trial — Image source: Shutterstock

Trial Progress and Medical Impact

The ACCENT study is evaluating Amplia’s novel FAK (focal adhesion kinase) inhibitor, narmafotinib, when used alongside the established chemotherapy combination of gemcitabine and Abraxane. The therapy aims to tackle both primary pancreatic tumors and secondary liver metastases, a common challenge in late-stage patients.

In this instance, the patient exhibited significant shrinkage of both liver metastases and the original pancreatic tumor. Following surgical removal of the tumors, pathological examination confirmed the absence of live cancer cells, officially qualifying the outcome as a pCR.

This level of response is extremely rare, especially in cases of metastatic pancreatic cancer. While around 5% of patients with locally advanced forms of the disease can reach a pCR with neoadjuvant chemotherapy, such outcomes are almost unheard of in metastatic cases. A pCR is often associated with extended survival outcomes, making this result noteworthy for clinicians and researchers alike.

Clinical Significance and Future Outlook

Amplia’s management expressed optimism about the clinical potential of narmafotinib, describing the pCR as a significant outcome for the patient and a strong signal of the therapy’s promise. The development supports ongoing research into narmafotinib's effectiveness and may inform future treatment strategies for advanced pancreatic cancer.

Adding to the momentum, the US Food and Drug Administration granted fast-track designation to narmafotinib in recognition of its potential to outperform current treatment options for serious conditions. This designation enables a faster path to clinical review and potential availability, accelerating access for patients in need.

The results from this trial represent a meaningful advancement in the fight against one of the most challenging cancers, highlighting the potential of next-generation targeted therapies like narmafotinib. As the ACCENT trial progresses, further data will shed light on its broader impact and suitability in wider patient populations.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.